Hepatic decompensation in patients with HIV/Hepatitis B Virus (HBV)/Hepatitis C Virus (HCV) triple infection versus HIV/HCV coinfection and the effect of Anti-HBV Nucleos(t)ide therapy

Vincent Lo Re, Li Wang, Scott Devine, Onur Baser, Temitope Olufade

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

The incidence rate of hepatic decompensation was higher in patients with human immunodeficiency virus (HIV)/hepatitis B virus (HBV)/hepatitis C virus (HCV) triple infection than in those with HIV/HCV coinfection (24.1 vs 10.8 events per 1000 person-years; hazard ratio [HR], 1.89; 95% confidence interval [CI], 1.12-3.18). Compared with HIV/HCVinfected patients, the rate of decompensation was increased among HIV/HBV/HCV-infected patients receiving no anti- HBV therapy (HR, 2.48; 95% CI, 1.37-4.49) but not among those who did receive such therapy (HR, 1.09; 95% CI, .40-2.97).

Original languageEnglish (US)
Pages (from-to)1027-1031
Number of pages5
JournalClinical Infectious Diseases
Volume59
Issue number7
DOIs
StatePublished - Oct 1 2014
Externally publishedYes

Keywords

  • End-stage liver disease
  • HIV
  • Hepatic decompensation
  • Hepatitis B
  • Hepatitis C

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Hepatic decompensation in patients with HIV/Hepatitis B Virus (HBV)/Hepatitis C Virus (HCV) triple infection versus HIV/HCV coinfection and the effect of Anti-HBV Nucleos(t)ide therapy'. Together they form a unique fingerprint.

Cite this